D. E. Shaw & Co., Inc. Iovance Biotherapeutics, Inc. Call Options Transaction History

D. E. Shaw & Co., Inc.

4 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q2 2024 Aug 14, 2024	SELL	$7.78 - $14.19 $362,548 - $661,254	-46,600 Reduced 67.15%	22,800 $182,000
Q1 2024 May 15, 2024	BUY	$7.59 - $17.47 $526,746 - $1.21 Million	69,400 New	69,400 $1.03 Million
Q2 2020 Aug 14, 2020	SELL	$27.21 - $41.0 $544,200 - $820,000	-20,000 Reduced 50.0%	20,000 $549,000
Q1 2020 May 15, 2020	BUY	$19.54 - $38.85 $781,600 - $1.55 Million	40,000 New	40,000 $1.2 Million

314

241M

3.77M

1.7M

Ticker IOVA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 157,800,992
Market Cap $1.44B
Description
Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. It has six ongoing phase 2 clinical studies, including C-144-01, of its lead product candidate, lifileucel, for the treatment o...

Get notified when there are updates to the investment portfolio of D. E. Shaw & Co., Inc., based on Form 13F filings with the SEC.

Stay updated on D. E. Shaw & Co., Inc. with notifications on news.